SkinHealth Systems Inc.
The Beauty Health Company is a global medical aesthetics company whose products are used by professional providers, including dermatologists, plastic surgeons, medical spas, estheticians, spas, hotels, and other retailers. Its portfolio includes Hydrafacial skin treatments and devices, SkinStylus microneedling and nano-channeling products, and HydraScalp powered by Keravive scalp treatments. Hydrafacial uses a device to cleanse, extract, and hydrate skin, with optional serums and other treatment add-ons. The company also offers a mobile application for consumers and providers. The company earns money by selling treatment devices and recurring consumables, including single-use tips, solutions, and serums, to providers. It sells directly in some countries and through distributors or a hybrid model in others. Its Delivery Systems are manufactured and assembled at its facility in Long Beach, California, where it also operates leased distribution facilities.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SKIN in the last 30 days.
See all $SKIN insider activity →SkinHealth Systems (SKIN) reported Q3 2026 revenue of $69.2M, down 2.1% YoY but improving from prior quarters. GAAP gross margin was 68.2%, with operating income of $5M. Consumables grew 1.2% YoY, while equipment sales lagged. The company is focusing on improving execution, expanding its Hydrafacial franchise, and broadening its product portfolio.
SkinHealth Systems Inc (SKIN) reported Q3 2026 earnings, highlighting a return to growth in consumables. CEO Pedro Mala noted improvements in outreach to dormant accounts and early signs of success with the U.S. rental program, which aims to reduce upfront capital barriers. EMEA region showed early improvement, with Q3 year-over-year decline narrowing to 11.7%. The company is investing in R&D for new products, including a 2027 device launch and a next-generation HydroFacial for 2028.
SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SkinHealth Systems Reports Third Quarter 2026 Financial Results Long Beach, Calif., November 5, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial®, today announced financial results for the third
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning SKIN (SkinHealth Systems Inc.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 1 bearish.
Recent SKIN coverage spans corporate actions, earnings and financial news.
Earnings beat on the top line and operating income suggest short‑term upside.
The disclosed operational improvements and rental program may support near‑term revenue growth.
Updated 2026 financial guidance reflects improved profitability and lower expenses.
The upcoming earnings release may trigger short-term volatility as investors position ahead of the results.
The reverse split may cause short-term price volatility as the market adjusts to the new share structure.
AlphAI scores every news story that mentions SKIN with an AI model for sentiment and relevance, and aggregates insider trades from SkinHealth Systems Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SkinHealth Systems (SKIN) reported Q3 2026 revenue of $69.2M, down 2.1% YoY but improving from prior quarters. GAAP gross margin was 68.2%, with operating income of $5M. Consumables grew 1.2% YoY, while equipment sales lagged. The company is focusing on improving execution, expanding its Hydrafacial franchise, and broadening its product portfolio.
SkinHealth Systems Inc (SKIN) reported Q3 2026 earnings, highlighting a return to growth in consumables. CEO Pedro Mala noted improvements in outreach to dormant accounts and early signs of success with the U.S. rental program, which aims to reduce upfront capital barriers. EMEA region showed early improvement, with Q3 year-over-year decline narrowing to 11.7%. The company is investing in R&D for new products, including a 2027 device launch and a next-generation HydroFacial for 2028.
SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SkinHealth Systems Reports Third Quarter 2026 Financial Results Long Beach, Calif., November 5, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial®, today announced financial results for the third
SkinHealth Systems (NASDAQ: SKIN) will release Q3 2026 earnings on Nov. 5, 2026, followed by a conference call at 4:30 p.m. ET. The webcast and materials will be available on their investor relations website.
StoneX reiterated a Hold rating on The Beauty Health Company (SKIN) after its 1-for-20 reverse stock split. The stock is down 61% year-over-year, trading at $11.56, but is considered undervalued by InvestingPro. The company is shifting to a medtech-inspired model and expects to return to profitability this year. Q2 2026 revenue missed estimates at $72.1M, but adjusted EBITDA beat guidance at $17.0M.
SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Regulation FD Disclosure. SkinHealth Systems Announces Reverse Stock Split Shares expected to begin trading on split-adjusted basis on October 14, 2026 LONG BEACH, Calif. – October 9, 2026 – SkinHealth Systems (Nasdaq: SKIN) (the “Company”), home to flagship brand Hydrafacial™, today announced that its Bo
SkinHealth Systems (SKIN) announced a 1-for-20 reverse stock split, effective October 14, 2026, to comply with Nasdaq's $1 minimum bid price requirement. The split will reduce outstanding shares from 130.3 million to 6.5 million, with no change in ownership percentages. Trading will continue under the ticker SKIN.
SkinHealth Systems (SKIN) repaid $103.2 million in 1.25% Convertible Senior Notes due 2026, plus $0.6 million in accrued interest, on Sep 30, 2026. The Indenture was discharged, simplifying the company's capital structure. No penalties or exit fees were incurred.
SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement. On September 30, 2026, the remaining outstanding aggregate principal amount of the 1.25% Convertible Senior Notes due 2026 (the “Notes”) issued by SkinHealth Systems Inc. (the “Company”), pursuant to the Indenture, dated
SkinHealth Systems (SKIN) has expanded its SkinStylus SteriLock MicroSystem, a professional microneedling and nano-needling device, to Europe. The launch includes the UK, Ireland, Germany, France, Spain, and Portugal, leveraging the company's existing Hydrafacial commercial network. The expansion aims to broaden SkinHealth Systems' medical aesthetics ecosystem and offer complementary solutions for various skin concerns.
